Ovarian Cancer
Ovarian Cancer Detected Early With DNA From Pap Smear in Proof-of-Principle Study
Researchers developed an early ovarian cancer test based on DNA from Pap smears from women who went on to develop high-grade serous ovarian cancer.
Investigational Cancer Drug Deemed Highly Mutagenic in Cell Line Sequencing Study
Using whole-genome sequencing on drug-exposed cell lines, researchers saw high mutation rates in control cell lines intermittently treated with a compound called CX-5461.
The assay distinguishes high-grade serous ovarian cancer tumors from benign masses using cell-free DNA methylation.
FDA Grants Marketing Authorization for Invitae Hereditary Cancer DNA Sequencing Test
The Invitae Common Hereditary Cancers Panel is the first test of its kind to obtain FDA marketing authorization, creating an easier pathway for similar tests.
Omitting pre- and post-test genetic counseling did not increase distress for participants in the MAGENTA trial compared to those who received more counseling.